FTC Rushes Patent Settlement Report In Push For Super Committee Action On "Pay-For-Delay"
Executive Summary
The Federal Trade Commission rushed to press the data about the number of patent settlements between brand and generic companies in FY 2011 in an apparent effort to grab the attention of the Joint Select Committee on Deficit Reduction.
You may also be interested in...
“Pay-For-Delay” Fight Is Now: FTC, GPhA Spar Over Report In Prelude To Supreme Court Review
Of the 140 brand-generic patent settlements in FY 2012, 40 contained both compensation to the generic manufacturer and a restriction on generic entry; FTC announces this record number as its suit against Watson goes to Supreme Court.
Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010
As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.